Pharmaceutical Executive
October 01, 2008
Features
0
0
Manufacturers overpay PBMs millions of dollars each year in rebates overpayments. Here's how to stop the leakage.
October 01, 2008
Columns
0
0
It's management makeover time-and micromanaging is so last year.
October 01, 2008
Features
0
0
Japan is playing a game of catch-up, dropping big cash on biotechs and risky acquisitions. But with patents expiring and sales falling, can they really pay their way to global success?
October 01, 2008
Leadership
0
0
Try this one on for size: Multi-tasking isn't the path to greatness
October 01, 2008
Features
0
0
Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works.
October 01, 2008
Global Report
0
0
Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems
October 01, 2008
Columns
0
0
What's the buzz all about? Word of mouth is more effective than we think.
October 01, 2008
Features
0
0
Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug.
October 01, 2008
Back Page
0
0
A head-to-head comparison of the Drug Vote '08
October 01, 2008
Columns
0
0
Web analystics is helping a new generation of pharma web sites get engaged.
October 01, 2008
From the Editor
0
0
A vision of pharma's next business model is starting to emerge. But how do we get from here to there?
October 01, 2008
Washington Report
0
0
Congressional leaders ready campaign to curb Medicare drug plans.
October 01, 2008
Columns
0
0
Enter the Maturity Matrix: the future of KOL management organization.
October 01, 2008
Thought Leader
0
0
Cubist Pharmaceuticals CEO Michael Bonney has given the company a successful start-and is now predicting the future of drug resistance.
October 01, 2008
Features
0
0
Clinical trials need to change. A recent survey shows that industry should address the research supply chain for the greatest gains in effciency.